Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0RMBUN
ADC Name	IMGC-936
Synonyms	IMGC936; IMGC 936 Click to Show/Hide
Organization	ImmunoGen, Inc.; MacroGenics, Inc.
Drug Status	Phase 1/2
Indication	In total 7 Indication(s) Breast cancer [ICD11:2C60-2C65] Phase 2 Colorectal cancer [ICD11:2B91] Phase 2 Gastric cancer [ICD11:2B72] Phase 2 Non-small cell lung cancer [ICD11:2C25] Phase 2 Pancreatic cancer [ICD11:2C10] Phase 2 Esophageal cancer [ICD11:2B70] Phase 1 Metastatic breast cancer [ICD11:2C6Y] Phase 1
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	MGA021		Antibody Info
Antigen Name	Disintegrin and metalloproteinase domain-containing protein 9 (ADAM9)		Antigen Info
Payload Name	DM21-C		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Tripeptide linker		Linker Info
Conjugate Type	Site-specific conjugation through the engineered cysteine 442 (CYSMAB).
Combination Type	DM21-C
Puchem SID	471299317 , 474492571 , 476000966
ChEBI ID	CHEMBL5095346

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT04622774	Phase 1	A phase 1/2, first-in-human, open-label, dose-escalation and expansion study of IMGC936 (Anti-ADAM9 antibody drug conjugate) in patients with advanced solid tumors.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT04622774	Clinical Status	Phase 1
Clinical Description	A phase 1/2, first-in-human, open-label, dose-escalation and expansion study of IMGC936 (Anti-ADAM9 antibody drug conjugate) in patients with advanced solid tumors.
Primary Endpoint	During dose escalation measure incidence and severity of Treatment Emergent Adverse Events, During dose escalation characterize dose-limiting toxicities (DLTs), During expansion describe the overall response rate.
Other Endpoint	During dose escalation and expansion to characterize study drug concentration and the concentration of anti-drug antibody, During dose expansion describe the duration of response and progression free survival, During dose escalation to describe the objective response rate and duration of response, During dose expansion measure incidence and severity of Treatment Emergent Adverse Events. Click to Show/Hide

References

Ref 1	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors, NCT04622774